Equities Research Analysts’ New Coverage for June 22nd (AGMB, ALT, BBOT, CASY, CNXU, DCH, EL, FTH, GPN, MUSA)

Equities Research Analysts’ new coverage for Monday, June 22nd:

HC Wainwright started coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB). The firm issued a buy rating and a $35.00 target price on the stock.

Leerink Partners assumed coverage on shares of Altimmune (NASDAQ:ALT). They issued an outperform rating and a $10.00 price target on the stock.

Oppenheimer Holdings, Inc. assumed coverage on shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT). Oppenheimer Holdings, Inc. issued an outperform rating and a $22.00 price target on the stock.

Capital One Financial Corporation started coverage on shares of Casey’s General Stores (NASDAQ:CASY). The firm issued an equal weight rating and a $896.00 price target on the stock.

HC Wainwright initiated coverage on shares of Conexeu Sciences (NASDAQ:CNXU). The firm issued a buy rating and a $20.00 target price on the stock.

Barclays PLC assumed coverage on shares of American Axle & Manufacturing (NYSE:DCH). Barclays PLC issued an equal weight rating and a $8.00 target price on the stock.

The Goldman Sachs Group, Inc. initiated coverage on shares of Estee Lauder Companies (NYSE:EL). The firm issued a buy rating and a $100.00 price target on the stock.

HC Wainwright started coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH). HC Wainwright issued a buy rating and a $60.00 price target on the stock.

Morgan Stanley assumed coverage on shares of Global Payments (NYSE:GPN). Morgan Stanley issued an equal weight rating and a $65.00 price target on the stock.

Capital One Financial Corporation initiated coverage on shares of Murphy USA (NYSE:MUSA). Capital One Financial Corporation issued an overweight rating and a $710.00 target price on the stock.

Citizens Jmp began coverage on shares of National Research (NASDAQ:NRC). The firm issued a market outperform rating and a $23.00 target price on the stock.

Chardan Capital began coverage on shares of Tenax Therapeutics (NASDAQ:TENX). Chardan Capital issued a buy rating and a $27.00 price target on the stock.